MAGNASENSE AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4005 SEK | -5.43% |
|
-6.86% | -65.77% |
| Jul. 08 | Sweden's AegirBio Changes Name to Magnasense | MT |
| Jul. 08 | AegirBio AB has Changed its Name to Magnasense AB | CI |
| Sales 2022 | 1.71 17.98 | Sales 2023 | 0.09 0.97 | Capitalization | 36.13M 381M |
|---|---|---|---|---|---|
| Net income 2022 | -363M -3.83B | Net income 2023 | -59M -622M | EV / Sales 2022 | 20,730,843 x |
| Net cash position 2022 | 7.44M 78.35M | Net Debt 2023 | 23.66M 249M | EV / Sales 2023 | 649,847,174 x |
| P/E ratio 2022 |
-0.11
x | P/E ratio 2023 |
-0.49
x | Employees | 14 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 91.27% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -3.31% | ||
| 1 week | -4.77% | ||
| Current month | -14.33% | ||
| 1 month | -21.70% | ||
| 3 months | -39.78% | ||
| 6 months | -57.32% | ||
| Current year | -65.00% |
1 week
0.39
0.44
1 month
0.390.72
Current year
0.391.17
1 year
0.391.80
3 years
0.39399.50
5 years
0.39399.50
10 years
0.39399.50
| Managers | Title | Age | Since |
|---|---|---|---|
Marco Witteveen
CEO | Chief Executive Officer | - | 23-06-14 |
| Director of Finance/CFO | 57 | 23-04-18 | |
Vasiliki Fragkou
COO | Chief Operating Officer | 45 | Oct. 31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Fredrik Häglund
BRD | Director/Board Member | 49 | 20-04-30 |
William Vickery
BRD | Director/Board Member | 57 | 22-05-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-10 | 0.4005 | -5.43% | 583 420 |
| 24-07-09 | 0.4235 | -1.05% | 175,302 |
| 24-07-08 | 0.428 | +3.88% | 169,387 |
| 24-07-05 | 0.412 | -3.85% | 153,468 |
| 24-07-04 | 0.4285 | -0.35% | 141,879 |
Delayed Quote Nasdaq Stockholm, July 10, 2024 at 08:22 am EDT
More quotes
AegirBio AB is a Sweden-based medicine company focused therapeutic drug monitoring of biologic therapies in the autoimmune, oncology and neurology space. The Company offers tests to monitor and optimize the dosage of biological drugs via its patented technology platform. It aims to provide personalized treatment by tracking drugs levels in individuals. Aegirbio combines core technologies from LifeAssays and Abreos Biosciences. LifeAssays is a diagnostics company based in Sweden, which owns the Magnia Point of Care and Point of Need reader technology. Abreos Biosciences is a California-based biotech, which is a developer of the Veritope chemistry platform for detecting levels of biologic drugs in patient samples.
Calendar
2024-08-22
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -65.00% | 1.45M | |
| +0.20% | 203B | |
| +3.65% | 178B | |
| +31.11% | 157B | |
| +32.35% | 112B | |
| +2.13% | 64.58B | |
| +22.60% | 56.33B | |
| -3.27% | 46.75B | |
| -9.79% | 36.59B | |
| -0.58% | 35.09B |
- Stock Market
- Equities
- AEGIR Stock
